Hosted on MSN

Recursion Pharmaceuticals outlines focused R&D pipeline with multiple catalysts through 2026

CEO Chris Gibson highlighted the company's strategic focus on the Recursion Operating System 2.0, emphasizing its capability to improve efficiency in drug discovery and development. Management ...
Hosted on MSN

Recursion Pharma to reduce workforce by 20%

Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) traded higher in the premarket on Tuesday after the AI-driven biotech announced plans to reduce its workforce by approximately 20% as part of a ...